CR20180456A - Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas - Google Patents

Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas

Info

Publication number
CR20180456A
CR20180456A CR20180456A CR20180456A CR20180456A CR 20180456 A CR20180456 A CR 20180456A CR 20180456 A CR20180456 A CR 20180456A CR 20180456 A CR20180456 A CR 20180456A CR 20180456 A CR20180456 A CR 20180456A
Authority
CR
Costa Rica
Prior art keywords
compositions
methods
alphaviruses
stabilize
living
Prior art date
Application number
CR20180456A
Other languages
English (en)
Inventor
Jill Ann; Livengood
Timothy Duane; Powell
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CR20180456A publication Critical patent/CR20180456A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Las modalidades aqui se refieren a las composiciones y metodos para estabilizar los alfavirus vivos. Otras modalidades se refieren a composiciones y metodos para reducir la degradación de alfavirus atenuados vivos. Ciertas modalidades se refieren a proporcionar una composición estabilizante mientras se reduce la reacción inmune en un sujeto a excipientes que estabilizan los alfavirus vivos proporcionando formulaciones mejoradas. Todavia otras modalidades se refieren a usos de composiciones descritas aqui en kits para aplicaciones portátiles y métodos en donde las composiciones reducen la degradación de los alfavirus vivos.
CR20180456A 2016-03-31 2017-03-27 Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas CR20180456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316262P 2016-03-31 2016-03-31
PCT/US2017/024365 WO2017172643A1 (en) 2016-03-31 2017-03-27 Compositions and methods for stabilizing alphaviruses with improved formulations

Publications (1)

Publication Number Publication Date
CR20180456A true CR20180456A (es) 2019-01-09

Family

ID=58537071

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180456A CR20180456A (es) 2016-03-31 2017-03-27 Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas

Country Status (19)

Country Link
US (2) US10632184B2 (es)
EP (1) EP3436063A1 (es)
JP (1) JP2019513138A (es)
KR (1) KR20180135912A (es)
CN (1) CN109069614A (es)
AU (1) AU2017241590A1 (es)
BR (1) BR112018069035A2 (es)
CA (1) CA3019529A1 (es)
CO (1) CO2018010357A2 (es)
CR (1) CR20180456A (es)
DO (1) DOP2018000211A (es)
EC (1) ECSP18081486A (es)
MX (1) MX2018011837A (es)
NI (1) NI201800096A (es)
PE (1) PE20190149A1 (es)
PH (1) PH12018502119A1 (es)
SG (1) SG11201808458QA (es)
SV (1) SV2018005747A (es)
WO (1) WO2017172643A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015097650A1 (en) 2013-12-23 2015-07-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
WO2021028406A1 (en) * 2019-08-09 2021-02-18 Valneva Se Chikungunya vaccine formulations
EP4010016A1 (en) * 2019-08-09 2022-06-15 Valneva SE Single shot chikungunya virus vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
EP2073839B1 (en) 2006-09-01 2016-10-19 Bharat Biotech International Limited A vaccine for chikungunya virus infection
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
SG11201507462QA (en) 2013-03-14 2015-10-29 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗

Also Published As

Publication number Publication date
SG11201808458QA (en) 2018-10-30
ECSP18081486A (es) 2019-01-31
PH12018502119A1 (en) 2019-07-15
US20200306361A1 (en) 2020-10-01
DOP2018000211A (es) 2018-12-31
NI201800096A (es) 2019-02-01
US10632184B2 (en) 2020-04-28
BR112018069035A2 (pt) 2019-01-29
AU2017241590A1 (en) 2018-10-11
CN109069614A (zh) 2018-12-21
PE20190149A1 (es) 2019-01-22
WO2017172643A1 (en) 2017-10-05
JP2019513138A (ja) 2019-05-23
SV2018005747A (es) 2019-03-28
CA3019529A1 (en) 2017-10-05
MX2018011837A (es) 2019-02-13
KR20180135912A (ko) 2018-12-21
US20190111124A1 (en) 2019-04-18
CO2018010357A2 (es) 2019-05-21
EP3436063A1 (en) 2019-02-06

Similar Documents

Publication Publication Date Title
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CL2019000473A1 (es) Compuestos de pirrolizina sustituida y usos de los mismos.
CL2018000162A1 (es) Composiciones ingeribles por abejas, procedimientos para el uso de las mismas para producir miel y miel producida de esta manera
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
PE20180267A1 (es) Composiciones que comprenden cepas bacterianas
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2015002433A1 (es) Imidazopiridazinas sustituidas
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
DOP2018000211A (es) Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
AR114780A1 (es) Formulaciones estables de inmunoconjugado anti-cd79b
MX2019000177A (es) Formulaciones de anticuerpos.
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CR20150553A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
AR102376A1 (es) Método de tratamiento para anti-brote de tubérculos con cantidad reducida de cipc
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas
AR113514A1 (es) Composiciones y métodos para mejorar la utilización del fósforo y el calcio en la dieta de los animales
CL2016001350A1 (es) Composiciones de ketoprofeno de accion prologanda.